Table 2.

General characteristics of included studies (about the relationships between Nestin expression and OS or PFS in glioma patients)

First author	Year	Origin country	No. of patients	Median/mean age (year)	WHO grade	Detect method	Cut off level	Survival end points	Follow up period	Survival analysis	Adjusted variables
Hatanpa [19]	2014	USA	50	median 37.5 years (20–66)	II–III	IHC	median	OS	4.3 year	multivariate (KM)	nestin, IDH, WHO grade, oligodendroglioma component (astrocytoma or oligoastrocytoma), MIB-1, age, sex, extent of resection and type of adjuvant, therapy
Milde [20]	2012	Russia	379	NR	II–III	IHC	50 %	OS	median 53 months	multivariate	cytogenetic group only, or cytogenetic group and posterior fossa group
								PFS
wan [21]	2011	Germany	283	NR	II–IV	IHC	median	OS	Mean 11.21 ± 4.26 years	multivariate	WHO grade, patient age at diagnosis and extent of resection
Kim [12]	2011	Korea	88	mean 54.9 years (13–80)	IV	IHC	50 %	OS	mean 13.9 (1–53) months	multivariate	age, sex, KPS, extent of removal, chemoradiotherapeutic modality, temozolomide modality, after temozolomide therapy and stem cell marker expression
								PFS
Arai [22]	2012	Japan	64	median 55 years (11–79)	III–IV	IHC	60 %	OS	1–67 months	KM	NR
Dahlrot [18]	2014	Denmark	25	NR	II	IF	median	OS	Media 12 months	multivariate	age, performance status (PS) and IDH1 status
								PFS
Dahlrot [18]	2014	Denmark	26	NR	III	IF	median	OS	Media 12 months	multivariate	age, performance status (PS) and IDH1 status
								PFS
Dahlrot [18]	2014	Denmark	185	NR	IV	IF	median	OS	Media 12 months	multivariate	age, performance status (PS) and IDH1 status